Natixis’s Protagonist Therapeutics PTGX Stock Holding History

Natixis’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-42,040	Closed	-$2.32M	–	1199
2025 Q2	$2.32M	Buy	+42,040	New	+$2.02M	0.01%	468

Other funds holding PTGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Natixis's PTGX Position: Q3 2025 in Review

Natixis sold out of Protagonist Therapeutics (PTGX) in Q3 2025, closing a stake of 42,040 shares — an estimated $2.32M sold.

Natixis first reported a position in PTGX in Q2 2025 and held it in 1 quarter. The position peaked at $2.32M in Q2 2025. 274 funds tracked by Wall St. Rank hold PTGX as of Q3 2025.

Natixis reported no remaining Protagonist Therapeutics position as of Q3 2025 after selling out during the quarter.
Natixis sold 42,040 Protagonist Therapeutics shares in Q3 2025, an estimated $2.32M.
Natixis first reported a position in Protagonist Therapeutics in Q2 2025 and held it in 1 quarter.
Natixis's Protagonist Therapeutics position peaked at $2.32M in Q2 2025.
274 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2025.

Based on Natixis's 13F filing for Q3 2025, filed 14 Nov 2025.